Stay updated with breaking news from Tak 279. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis. ....
Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis. ....
Japan: Takeda has announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment. ....